Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy

转甲状腺素 淀粉样变性 医学 耐受性 心肌病 药效学 心脏淀粉样变性 内科学 心力衰竭 药代动力学 药理学 病理 不利影响
作者
Susy Kotit
出处
期刊:Global Cardiology Science and Practice [Magdi Yacoub Institute]
卷期号:2023 (1) 被引量:14
标识
DOI:10.21542/gcsp.2023.4
摘要

Introduction: Transthyretin amyloidosis (ATTR amyloidosis) is a progressive fatal disease characterized by accumulation of amyloid fibrils composed of misfolded transthyretin (TTR) protein in tissues, resulting in cardiomyopathy and heart failure. Approximately 50,000 people have hereditary ATTR amyloidosis, and up to 500,000 have wild-type ATTR amyloidosis globally, leading to poor quality of life and high morbidity, resulting in death within a median of 2 to 6 years after diagnosis. However, data on the prevalence of ATTR-CM is limited and poorly characterized. NTLA-2001, an in vivo gene-editing therapeutic agent designed to treat ATTR amyloidosis by reducing the concentration of TTR in serum by knocking out the TTR gene, has been shown to be effective, presenting a new therapeutic strategy. However, the safety, tolerability, and pharmacodynamic response to IV NTLA-2001 administration has not been yet demonstrated. Study and results: The first-in-human in vivo CRISPR/Cas9 trial of TTR Gene editing by NTLA-2001 in patients with Transthyretin Amyloidosis and cardiomyopathy was designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic and pharmacodynamic responses to IV NTLA-2001 administration and its effect on serum transthyretin (TTR) levels in patients with ATTR amyloidosis and cardiomyopathy. Twelve subjects received NTLA-2001 (three NYHA I/II subjects at 0.7 mg/kg, three subjects at 1.0 mg/kg, and six NYHA III subjects at 0.7 mg/kg). Serum TTR levels were reduced from the baseline in all subjects (mean>90% after 28 days). Mean % reductions (+/-SEM) from baseline to day 28 were: NYHA I/II at 0.7 mg/kg = 92% (1%), at 1.0 mg/kg = 92% (2%), and for NYHA III at 0.7 mg/kg = 94% (1%) maintained through 4-6 months. Two of the 12 patients (16.7%) reported a transient infusion reaction. One patient experienced a grade 3 infusion-related reaction that resolved without any clinical sequelae. Lessons learned: This study showed a significant and consistent reduction in serum TTR protein levels after a single admission, while being generally well tolerated, representing a potential new option for the treatment and improvement of the prognosis of cardiac ATTR amyloidosis. Further research into the long-term safety and efficacy of NTLA-2001, particularly in higher-risk patients, including continued monitoring of whether knockout of the TTR gene results in sustained TTR reduction over the long term, is essential. Evaluation of the potential effects of markedly reduced TTR levels on patients' clinical outcomes, with a focus on functional capacity, quality of life, and mortality benefits are essential. The analysis of the use of this technology for an array of other diseases is vital.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cdercder的应助被tlc_191026采纳,获得30
2秒前
XY完成签到,获得积分20
2秒前
darkegg完成签到,获得积分10
3秒前
3秒前
3秒前
赵医生完成签到,获得积分10
3秒前
水弘的应助被陶醉的筮采纳,获得10
4秒前
daomaihu发布了新的文献求助100
4秒前
My_magnum_opus给gaoxueli的求助进行了留言
4秒前
xiaolizi发布了新的文献求助30
5秒前
852的应助被1192237414采纳,获得10
6秒前
赵医生发布了新的文献求助10
6秒前
Krositon发布了新的文献求助10
6秒前
7秒前
情怀的应助被panada采纳,获得10
7秒前
WEN完成签到,获得积分10
7秒前
Lucas的应助被Jonathan采纳,获得10
7秒前
小冯完成签到,获得积分10
8秒前
8秒前
matou发布了新的文献求助20
10秒前
Tinker完成签到,获得积分10
10秒前
11秒前
李仟亿发布了新的文献求助10
12秒前
12秒前
刘雨森完成签到,获得积分10
13秒前
Tink完成签到,获得积分0
13秒前
14秒前
水弘的应助被谦让的烨磊采纳,获得10
15秒前
思源的应助被野性的懿轩采纳,获得10
15秒前
人人人完成签到,获得积分10
15秒前
daomaihu发布了新的文献求助100
16秒前
酱鱼完成签到,获得积分10
16秒前
16秒前
Wangdx完成签到 ,获得积分10
16秒前
16秒前
田12完成签到,获得积分10
17秒前
酤贳发布了新的文献求助10
17秒前
科目三的应助被化学胖子采纳,获得10
17秒前
awdasd发布了新的文献求助10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183508
求助须知:如何正确求助?哪些是违规求助? 9572862
关于积分的说明 21827639
捐赠科研通 7780681
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480405